Search alternatives:
significant fold » significant force (Expand Search), significant co (Expand Search), significant all (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search), fold increases (Expand Search)
Showing 1 - 20 results of 4,957 for search '(( significant fold decrease ) OR ( significant ((point decrease) OR (mean decrease)) ))', query time: 0.37s Refine Results
  1. 1
    MiR-129-5p levels were decreased in mouse depression models.

    MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

    Published 2025
    “…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. …”
    Save to List
    Saved in:
  2. 2
    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1.

    IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

    Published 2025
    Save to List
    Saved in:
  3. 3
    (a) Mycelial diameter (mm) determination on PDA plates, (b) Inhibition diameters, and (c) inhibition percentages of <i>Aspergillus flavus</i> treated with <i>U. epigea</i> extract and Ag/ZnO nanoparticles (Biosynthesized (B) and Conventional (C) at various concentrations.

    (a) Mycelial diameter (mm) determination on PDA plates, (b) Inhibition diameters, and (c) inhibition percentages of <i>Aspergillus flavus</i> treated with <i>U. epigea</i> extract... by Martha Cebile Jobe (21175426)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session.

    Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

    Published 2025
    Save to List
    Saved in:
  5. 5
    Middle cerebral artery mean flow velocity at three time points.

    Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  6. 6
    HA-MAD1 tumors have increased CIN and decreased p53.

    HA-MAD1 tumors have increased CIN and decreased p53. by Sarah E. Copeland (13951506)

    Published 2024
    Save to List
    Saved in:
  7. 7
    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity.

    PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

    Published 2025
    Save to List
    Saved in:
  8. 8
    The mean and standard deviation of parameters.

    The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles.

    The catalase enzyme response of <i>A</i>. <i>albopictus</i> larvae decreased (1.5-fold) in response to <i>M</i>. <i>robertsii</i>-derived copper nanoparticles. by Perumal Vivekanandhan (4863484)

    Published 2024
    Save to List
    Saved in:
  10. 10
    a.) Mean FB ratios by sample. b) Mean FB ratios by racial group.

    a.) Mean FB ratios by sample. b) Mean FB ratios by racial group. by Zoë Dinkel (21402766)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Summary of post-treatment disease course measures from MDMA-AT publications.

    Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Study selection criteria.

    Study selection criteria. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.

    Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Disease course measures after the PTSD treatments.

    Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    PICOS criteria for the SLR.

    PICOS criteria for the SLR. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Summary of post-treatment CAPS score changes from MDMA-AT publications.

    Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Summary of post-treatment disease course measures from off-label medications clinical trials.

    Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.

    Summary of post-treatment CAPS score changes from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.

    Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Summary of post-treatment disease course measures from clinical trials with psychotherapies.

    Summary of post-treatment disease course measures from clinical trials with psychotherapies. by Filip Stanicic (17808254)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: